vs

Side-by-side financial comparison of FLEXIBLE SOLUTIONS INTERNATIONAL INC (FSI) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $9.1M, roughly 1.4× FLEXIBLE SOLUTIONS INTERNATIONAL INC). FLEXIBLE SOLUTIONS INTERNATIONAL INC runs the higher net margin — -5.1% vs -1398.3%, a 1393.3% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs -0.5%). FLEXIBLE SOLUTIONS INTERNATIONAL INC produced more free cash flow last quarter ($-4.0M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs -0.6%).

Flexible Solutions International Inc develops and manufactures specialty chemicals for water conservation, energy efficiency, and agricultural use. Core products include water body evaporative reduction solutions, farm crop yield additives, and swimming pool heat retention products, serving customers across North America and global agricultural markets.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

FSI vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.4× larger
RNA
$12.5M
$9.1M
FSI
Growing faster (revenue YoY)
RNA
RNA
+434.6% gap
RNA
434.0%
-0.5%
FSI
Higher net margin
FSI
FSI
1393.3% more per $
FSI
-5.1%
-1398.3%
RNA
More free cash flow
FSI
FSI
$152.8M more FCF
FSI
$-4.0M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
-0.6%
FSI

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
FSI
FSI
RNA
RNA
Revenue
$9.1M
$12.5M
Net Profit
$-460.9K
$-174.4M
Gross Margin
29.4%
Operating Margin
11.6%
-1513.5%
Net Margin
-5.1%
-1398.3%
Revenue YoY
-0.5%
434.0%
Net Profit YoY
-167.8%
-117.0%
EPS (diluted)
$-0.03
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FSI
FSI
RNA
RNA
Q4 25
$9.1M
Q3 25
$10.6M
$12.5M
Q2 25
$11.4M
$3.8M
Q1 25
$7.5M
$1.6M
Q4 24
$9.2M
$3.0M
Q3 24
$9.3M
$2.3M
Q2 24
$10.5M
$2.0M
Q1 24
$9.2M
$3.5M
Net Profit
FSI
FSI
RNA
RNA
Q4 25
$-460.9K
Q3 25
$-503.4K
$-174.4M
Q2 25
$2.0M
$-157.3M
Q1 25
$-277.7K
$-115.8M
Q4 24
$679.6K
$-102.3M
Q3 24
$611.9K
$-80.4M
Q2 24
$1.3M
$-70.8M
Q1 24
$457.2K
$-68.9M
Gross Margin
FSI
FSI
RNA
RNA
Q4 25
29.4%
Q3 25
23.9%
Q2 25
47.4%
Q1 25
26.1%
Q4 24
29.2%
Q3 24
40.9%
Q2 24
37.4%
Q1 24
30.6%
Operating Margin
FSI
FSI
RNA
RNA
Q4 25
11.6%
Q3 25
2.9%
-1513.5%
Q2 25
29.0%
-4448.7%
Q1 25
-0.9%
-8360.9%
Q4 24
9.4%
-4069.6%
Q3 24
20.5%
-4200.9%
Q2 24
18.7%
-4040.4%
Q1 24
8.3%
-2178.6%
Net Margin
FSI
FSI
RNA
RNA
Q4 25
-5.1%
Q3 25
-4.8%
-1398.3%
Q2 25
17.8%
-4089.3%
Q1 25
-3.7%
-7360.0%
Q4 24
7.4%
-3439.5%
Q3 24
6.6%
-3441.7%
Q2 24
12.3%
-3461.8%
Q1 24
5.0%
-1943.4%
EPS (diluted)
FSI
FSI
RNA
RNA
Q4 25
$-0.03
Q3 25
$-0.04
$-1.27
Q2 25
$0.15
$-1.21
Q1 25
$-0.02
$-0.90
Q4 24
$0.05
$-0.80
Q3 24
$0.05
$-0.65
Q2 24
$0.10
$-0.65
Q1 24
$0.04
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FSI
FSI
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
$4.4M
Stockholders' EquityBook value
$38.9M
$1.9B
Total Assets
$61.8M
$2.1B
Debt / EquityLower = less leverage
0.11×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FSI
FSI
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$10.0M
$243.9M
Q1 25
$11.0M
$254.2M
Q4 24
$10.0M
$219.9M
Q3 24
$13.0M
$370.2M
Q2 24
$9.2M
$575.8M
Q1 24
$8.3M
$471.4M
Total Debt
FSI
FSI
RNA
RNA
Q4 25
$4.4M
Q3 25
$7.1M
Q2 25
$7.5M
Q1 25
$8.1M
Q4 24
$8.8M
Q3 24
$9.4M
Q2 24
$8.3M
Q1 24
$8.0M
Stockholders' Equity
FSI
FSI
RNA
RNA
Q4 25
$38.9M
Q3 25
$39.0M
$1.9B
Q2 25
$39.4M
$1.2B
Q1 25
$38.4M
$1.3B
Q4 24
$38.0M
$1.4B
Q3 24
$36.9M
$1.5B
Q2 24
$36.2M
$1.2B
Q1 24
$36.0M
$830.9M
Total Assets
FSI
FSI
RNA
RNA
Q4 25
$61.8M
Q3 25
$58.4M
$2.1B
Q2 25
$58.2M
$1.4B
Q1 25
$61.7M
$1.5B
Q4 24
$60.0M
$1.6B
Q3 24
$57.8M
$1.6B
Q2 24
$56.3M
$1.3B
Q1 24
$57.6M
$951.5M
Debt / Equity
FSI
FSI
RNA
RNA
Q4 25
0.11×
Q3 25
0.18×
Q2 25
0.19×
Q1 25
0.21×
Q4 24
0.23×
Q3 24
0.25×
Q2 24
0.23×
Q1 24
0.22×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FSI
FSI
RNA
RNA
Operating Cash FlowLast quarter
$-3.0M
$-156.2M
Free Cash FlowOCF − Capex
$-4.0M
$-156.9M
FCF MarginFCF / Revenue
-44.3%
-1257.6%
Capex IntensityCapex / Revenue
11.7%
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-591.7K
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FSI
FSI
RNA
RNA
Q4 25
$-3.0M
Q3 25
$2.0M
$-156.2M
Q2 25
$5.3M
$-199.7M
Q1 25
$-544.3K
$-124.8M
Q4 24
$-2.2M
$-99.9M
Q3 24
$2.5M
$-65.6M
Q2 24
$5.9M
$-65.0M
Q1 24
$-604.8K
$-70.4M
Free Cash Flow
FSI
FSI
RNA
RNA
Q4 25
$-4.0M
Q3 25
$39.4K
$-156.9M
Q2 25
$4.3M
$-203.0M
Q1 25
$-898.4K
$-128.6M
Q4 24
$-4.3M
$-103.8M
Q3 24
$1.3M
$-67.3M
Q2 24
$4.7M
$-65.5M
Q1 24
$-1.1M
$-71.3M
FCF Margin
FSI
FSI
RNA
RNA
Q4 25
-44.3%
Q3 25
0.4%
-1257.6%
Q2 25
37.9%
-5277.1%
Q1 25
-12.0%
-8174.3%
Q4 24
-47.0%
-3491.0%
Q3 24
13.6%
-2881.8%
Q2 24
44.9%
-3204.6%
Q1 24
-11.7%
-2012.3%
Capex Intensity
FSI
FSI
RNA
RNA
Q4 25
11.7%
Q3 25
18.7%
5.7%
Q2 25
8.6%
86.9%
Q1 25
4.7%
238.6%
Q4 24
22.8%
131.7%
Q3 24
13.0%
72.9%
Q2 24
11.3%
26.0%
Q1 24
5.2%
25.8%
Cash Conversion
FSI
FSI
RNA
RNA
Q4 25
Q3 25
Q2 25
2.60×
Q1 25
Q4 24
-3.27×
Q3 24
4.05×
Q2 24
4.59×
Q1 24
-1.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons